Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07329673

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CCM Clinical Research Group

Miami, Florida, 33133, United States

Location status: Recruiting

Location contact

CCM Clinical Research Group

CONTACT

[email protected]

305-285-0705

Francisco Ricart, MD

PRINCIPAL_INVESTIGATOR

About this study

This study aims to evaluate the performance of QbMobile in children, adolescents, and adults assessed for and diagnosed with ASD (Autism Spectrum Disorder, MDD (Major Depressive Disorder), Bipolar Disorder, or Anxiety Disorder, or has a prior diagnosis of one of the included disorders but is not currently receiving treatment. Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinical visit. They will then repeat the test remotely the following day at the same time as the previous test +/-3 hours. Participants will be asked to complete QbMobile prior to initiating any treatment.

Note on Outcome Measures Presentation:

The IRB-approved protocol defines endpoints broadly (e.g., identification of QbMobile domain profiles, classification accuracy, variability, and exploratory analyses). To comply with ClinicalTrials.gov requirements that each outcome measure represent a single assessment with a single unit of measure, these endpoints are operationalized into separate outcome measures corresponding to individual QbMobile metrics (domain SD-scores, Total Score [0-100], accuracy percentages, variability estimates).

This operationalization does not introduce new scientific endpoints or alter study objectives, design, or analyses. It ensures clarity and compliance for registry reporting while maintaining alignment with the approved protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
  • Aged > 6 years and < 60 years old;
  • Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;
  • Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;
  • Have adequate sensory and physical ability to complete QbMobile;
  • Possess or have access to an iPhone model that supports QbMobile.

Exclusion criteria

  • Intellectual disability designated by IQ<70;
  • Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;
  • Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation);
  • Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);
  • Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
  • Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;
  • Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.

Treatment and study plan

Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)

Device

Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study.

Primary outcomes

  1. Identification of QbMobile Domain Profiles Using SD-Scores and Total Score (0-100)

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)

    QbMobile is a software application that measures cognitive performance and activity levels, including attention, impulsivity, activity, and movement patterns. The study will identify statistically distinct QbMobile domain profiles for each diagnostic group (ASD, MDD, Bipolar Disorder, Anxiety Disorder) using domain SD-scores and the QbMobile Total Score (0-100). (Component metrics are listed as secondary outcomes to meet single-measure reporting requirements.)

Secondary outcomes

  1. QbMobile Domain SD-Scores (Attention, Impulsivity, Activity, Movement) - Group Differences

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)

    QbMobile is a software application that measures cognitive performance and activity levels. Domain scores will be analyzed as SD-scores to assess differences among diagnostic groups (ASD, MDD, Bipolar Disorder, Anxiety Disorder).

  2. QbMobile Total Score (0-100) - Group Differences

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)

    QbMobile is a software application that measures cognitive performance and activity levels. The Total Score (0-100; higher values indicate greater likelihood of ADHD symptomatology) will be compared across diagnostic groups to assess differences.

  3. Classification Accuracy Using QbMobile Domain SD-Scores

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)

    QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using domain SD-scores; metrics will include sensitivity, specificity, and predictive values.

  4. Classification Accuracy Using QbMobile Total Score (0-100)

    Time frame: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2)

    QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using the Total Score; metrics will include sensitivity, specificity, and predictive values based on prespecified thresholds.

  5. Comparison of QbMobile Domain SD-Scores with Normative Dataset

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).

    QbMobile is a software application that measures cognitive performance and activity levels. Domain SD-scores will be compared with the age- and sex-adjusted normative dataset to identify differences between diagnostic groups and normative patterns.

  6. Comparison of QbMobile Total Score (0-100) with Normative Distribution

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).

    QbMobile is a software application that measures cognitive performance and activity levels. Total Scores will be compared with the normative distribution to identify deviations from expected values.

  7. Variability in Differentiation Using QbMobile Domain SD-Scores

    Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).

    QbMobile is a software application that measures cognitive performance and activity levels. Variability in group differentiation will be assessed using domain SD-scores (e.g., confidence intervals and variance estimates across repeated measures).

  8. Variability in Differentiation Using QbMobile Total Score (0-100)

    Time frame: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).

    QbMobile is a software application that measures cognitive performance and activity levels. Variability will be assessed using Total Scores (e.g., confidence intervals and variance estimates across repeated measures).

  9. Exploratory Analysis of Additional QbMobile Domain Parameters (SD-Based)

    Time frame: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).

    Consistent with the protocol statement that "all data collected from QbMobile during this study will be available to explore additional domain parameters," exploratory analyses will examine QbMobile domain data using SD-based metrics to identify additional parameters for further analysis.

  10. Exploratory Analysis of Additional QbMobile Parameters from Total Score and Raw Performance Data

    Time frame: Visit 1 (clinic) and Visit 2 (remote, next day).

    Consistent with the protocol statement that "all data collected from QbMobile… will be available to explore additional domain parameters," exploratory analyses will use the QbMobile Total Score (0-100) and raw performance data (e.g., response time, error counts, movement traces) to identify additional parameters for further analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Ragini Sanyal

CONTACT

[email protected]

Robert Nolen

CONTACT

[email protected]

18325370300

Sponsors and collaborators

Lead sponsor

Qbtech AB

Industry

Registry information

Official study title

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms.

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 9, 2026
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.